The indications for revascularization of the renal arteries are the subject of continuing controversy. Based on the results of the STAR and ASTRAL trials, the practice of indiscriminately revascularizing atherosclerotic RAS is no longer tenable. The challenge is to identify those selected patients who would respond, and to intervene early enough to reverse kidney damage. Intervention is not recommended if renal function has remained stable over the past 6-12 months and if hypertension can be controlled with an acceptable medical regimen. Anatomically relevant RAS.70% should be verified by functional measurements as systolic pressure gradient ≥21 mmHg or Pd/Pa pressure ratio of 0.9. The best evidence supporting intervention seems to be for bilateral stenosis with 'flash' pulmonary oedema unrelated to acute coronary syndrome, but the evidence is from retrospective studies. Indeed, in patients with atherosclerotic RAS, control of hypertension may be facilitated by revascularization, but cure of hypertension is unusual, and preservation of renal function may be a more realistic goal. The choice of revascularization technique depends on the presence of associated aortoiliac diseases. For complicated cases, surgical revascularization and renal bypass are both acceptable. Novel approaches to attenuate kidney tissue injury and increase its viability regardless of revascularization may prove vital and are under investigation.
Advances in antihypertensive drug therapy and intensive risk factor management including smoking cessation and statin therapy can provide excellent blood pressure control for many individuals. Despite extensive observational experience with renal revascularization in patients with renovascular hypertension, recent prospective randomized trials fail to establish compelling benefits either with endovascular stents or with surgery when added to effective medical therapy. These trials are limited and exclude many patients most likely to benefit from revascularization. Meaningful recovery of kidney function after revascularization is limited once fibrosis is established. Recent experimental studies indicate that mechanisms allowing repair and regeneration of parenchymal kidney tissue may lead to improved outcomes in the future. Until additional staging tools become available, clinicians will be forced to individualize therapy carefully to optimize the potential benefits regarding both blood pressure and renal function for such patients. 
Experimental-Tx 947 patients
To determine the effects of renal-artery stenting on the incidence of important cardiovascular and renal adverse events.
Over a median follow-up period of 43 months (interquartile range, 31 to 55), the rate of the primary composite end point did not differ significantly between participants who underwent stenting in addition to receiving medical therapy and those who received medical therapy alone (35.1% and 35.8%, respectively; hazard ratio with stenting, 0.94; 95% CI, 0.76 to 1.17; P=0.58). There were also no significant differences between the treatment groups in the rates of the individual components of the primary end point or in allcause mortality. During follow-up, there was a consistent modest difference in systolic blood pressure favoring the stent group (-2.3 mm Hg; 95% CI, -4.4 to -0.2; P=0.03). In 121 patients with and without diastolic hypertension but free of renal-artery disease it was established that the "appearance time" of injected contrast medium is equal in both kidneys and generally occurs 2 or 3 minutes after injection. Abnormalities in the rapidsequence pyelogram were noted in 39/42 patients with renovascular hypertension. The rapid-sequence pyelogram compares favorably with the radioisotope renogram and individual kidney-function tests as a screening procedure for renovascular hypertension. To determine the apparent prevalence of renal parenchymal and reversible, secondary hypertension.
The combined occurrence of an elevated serum creatinine level plus 1 or more urinary abnormalities was noted in 0.95%. Initial review of case reports revealed 6 participants with hypertension secondary to use of birth control pills and 3 participants with hypertension that was proved to be secondary to renovascular disease. Specific laboratory or historical criteria were used as indications for more intensive investigation in an additional 65 participants. Among these individuals, 1 participant with renovascular disease and 3 with possible primary hyperaldosteronism were identified. A rapid-sequence IVU or radionuclide scan was performed on another subgroup of 62 participants whose hypertension was "poorly" controlled (diastolic blood pressure, ≥95 mm Hg). 59 studies were negative, 1 was positive, and 2 were equivocal. These results suggest that the frequency of clinically relevant cases of reversible, secondary hypertension, at least among individuals with mild to moderate elevation of blood pressure, is low. 
Experimental-Dx 5 stents
To quantitatively estimate the shielding and susceptibility effects of commonly used metallic stents on MR signal.
The factor characterizing susceptibility effects was estimated from the signal phase of the first experiment, and then the factor characterizing the shielding effects was derived from the second experiment. Susceptibility induced signal loss was negligible (<1%) for nonstainless-steel (nitinol, platinum, and cobalt-alloy) stents and totally destructive (100%) for the stainless steel stent. Signal loss due to RF shielding was 31%-62% for nitinol stents, 14%-50% for platinum stents, 50%-77% for the cobaltalloy stents (undetermined for the stainless steel stent), varied with stent orientation, diameter, and wall geometry. 
Observational-Dx 46 patients; 2 readers
Prospective study to compare contrastenhanced 3D MRA with MDCT in the same patients for assessment of the aortoiliac and renal arteries. DSA is the standard of reference.
Sensitivity of MRA for detection of hemodynamically significant arterial stenosis was 92% for reader 1 and 93% for reader 2, and specificity was 100% and 99%, respectively. Sensitivity of CTA was 91% for reader 1 and 92% for reader 2, and specificity was 99% and 99%, respectively. Differences between the 2 modalities were not significant. Interobserver and intermodality agreement was excellent (kappa = 0.88-0.90). The time for performance of 3D reconstruction and image analysis of CT data sets was significantly longer than that for MR data sets (P<.001 To assess inter-observer agreement in the interpretation of renal angiograms.
Comparison of the assessment of renal angiograms by 3 experienced radiologists. Agreement about the number of renal arteries was reasonable (kappa = 0.50-0.72), as was agreement about the presence of stenosis (kappa = 0.68-0.86). Agreement about stenosis location and aspect was poor (kappa = 0.26-0.47 and kappa = 0.15-0.26, respectively). There was general agreement about the severity of stenosis (weighted kappa = 0.65-0.70), but it was not possible to distinguish between 50% and 60% stenosis or between 60% and 70% stenosis (kappa <0.40). No correlation was found between agreement on severity of stenosis and the quality of the images. Review/Other-Dx 15 patients To define "significant" RAS (ie, a stenosis able to induce arterial hypertension).
For a P(d)/P(a) ratio >0.90, no significant change in plasma renin concentration was observed. However, when P(d)/P(a) became <0.90, a significant increase in renin was observed in the renal vein of the stenotic kidney, finally reaching a maximal increase of 346 +/-145% for P(d)/P(a) of 0.50 (P=0.006). These values returned to baseline when the stenosis was relieved. In addition, plasma renin concentration increased significantly in the vein from the nonstenotic kidney (P=0.02). In renal artery stenoses, a P(d)/P(a) ratio of 0.90 can be considered a threshold value below which the stenosis is likely responsible for an up-regulation of renin production and, thus, for renovascular hypertension. These findings might contribute to better patient selection for renal angioplasty. EVIDENCE To evaluate whether translesional pressure gradients could identify the patients with RAS who might benefit from stenting.
Average reductions in systolic blood pressure and diastolic blood pressure at follow-up were -20±30 mm Hg and -2±12 mm Hg, respectively. At multivariate analysis, dopamine-induced mean gradient was the only independent predictor of the variations of both systolic blood pressure (regression coefficient = -4.03, standard error = 1.11; P<0.001) and diastolic blood pressure (regression coefficient = -3.11, standard error = 1.20; P=0.009). Patients who showed a decline in systolic blood pressure from the baseline value >20 mm Hg were considered as "responders." The optimal cutoff for identification of "responders" was a dopamine-induced mean gradient ≥20 mm Hg (area under the curve, 0.77; 95% CI, 0.64 to 0.90; P=0.001). A dopamine-induced mean pressure gradient of ≥20 mm Hg is highly predictive of arterial hypertension improvement after renal stenting, and therefore this measurement is useful for appropriate selection of patients with arterial hypertension. To determine the diagnostic value of highresolution 3D unenhanced ECG-gated respiratory-navigated MRA of the renal arteries using a steady-state free precession technique in comparison with 1.0-molar contrast-enhanced MRA in patients with suspected RAS.
Examination time was shorter for contrastenhanced MRA (mean ± SD, 12 ± 3 minutes) than for unenhanced MRA (19 ± 3 minutes; P<0.001). On a 5-point scale, the image quality was similar for contrast-enhanced MRA (3.8 ± 1.0) and unenhanced MRA (4.0 ± 1.3; P=0.24). Contrast-enhanced MRA offered more assessable data sets than did unenhanced MRA (95% vs 90%); however, unenhanced MRA had more data sets with maximum image quality (49% vs 30%). There was moderate agreement in stenosis grading between both MRA techniques (? = 0.51; P<0.001), but in only 1 case (1.3%) we found mismatch of more than 1 severity stenosis grade (stenoses >75%). Sensitivity, specificity, and PPV and NPV of unenhanced MRA to detect renal artery stenoses >50% were 75%, 99%, 75%, and 99%, respectively. We show that steady-state free precession 3D unenhanced MRA is a very promising technique for patients with suspected renovascular disease and could be used as an alternative if gadolinium-based contrast agents cannot be administered.
Review/Other-Dx
patients
To evaluate the efficacy of CO2 DSA for performing renal artery angioplasty in highrisk patients.
21 patients (13 men and 8 women) underwent 29 angioplasties (2 were bilateral and 6 were repeated). 4 kidney transplantation patients had ostial stenosis and the remaining 17 patients had nonostial stenosis. For all patients except 1, angioplasty initially was a technical success, as defined by a residual stenosis of <30%. Supplemental iodinated contrast material was used in only 6 patients (average dose, 8.5 ml). A range of 80-200 mL of carbon dioxide per procedure was used (average dose, 114.6 mL). 1 renal artery dissection occurred, which was unrelated to the carbon dioxide. There were no allergic reactions. The level of serum creatinine remained the same after 11 procedures, decreased after 12 procedures, and increased minimally after 4 procedures (<0.5 mg/dL). On the basis of our preliminary findings in a small group of patients, using carbon dioxide as an intravascular contrast agent to perform renal artery angioplasty in patients who have an allergy to iodinated contrast material or who suffer from renal insufficiency is safe and efficacious. Evidence Table Key Evidence Table Key Study Quality Category Definitions  Category 1 The study is well-designed and accounts for common biases.
 Category 2 The study is moderately well-designed and accounts for most common biases.  Category 3 There are important study design limitations.
 Category 4 The study is not useful as primary evidence. The article may not be a clinical study or the study design is invalid, or conclusions are based on expert consensus. For example: a) the study does not meet the criteria for or is not a hypothesis-based clinical study (e.g., a book chapter or case report or case series description); b) the study may synthesize and draw conclusions about several studies such as a literature review article or book chapter but is not primary evidence; c) the study is an expert opinion or consensus document. 
